Tirzepatide Delivers Up to 21% Weight Loss in Obesity
SURMOUNT-1 establishes the first dual GIP/GLP-1 receptor agonist as a high-efficacy antiobesity agent, achieving weight reductions approaching bariatric surgery in adults without diabetes.
Tirzepatide delivers unprecedented weight loss results in obesity management.
Obesity significantly impacts global health, and effective treatments are crucial for reducing related morbidity and mortality. Tirzepatide led to weight reductions of -15.0%, -19.5%, and -20.9% for 5 mg, 10 mg, and 15 mg doses, respectively, compared to -3.1% with placebo over 72 weeks. This phase 3 trial supports tirzepatide as an effective obesity treatment, although gastrointestinal side effects should be managed, especially during dose escalation. Tirzepatide shows promise as a significant weight reduction option for obesity management.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, SURMOUNT-1 Investigators
Citation:Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. The New England journal of medicine. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038